DRD2 and glioblastoma: The same authors subsequently demonstrated that one of these pathways, mediated by the dopamine receptor subtype 2 (DRD2), plays a critical role in glioblastoma mitogenic signaling and that DRD2 antagonists, clinically used as anti-psychotic drugs, harbor anti-glioblastoma activities [29–31].